Form 4: Heron Therapeutics CEO Granted Over 1.6M Equity Awards

Heron Therapeutics CEO Craig Collard was granted over 1.6 million restricted and performance stock units, vesting quarterly starting in 2026.

Summary

• Craig A. Collard, CEO and Director of Heron Therapeutics, Inc. (HRTX), was granted 800,337 Restricted Stock Units (RSUs) and 800,336 Performance Stock Units (PSUs) on January 30, 2026.
• The RSUs convert into common stock on a one-for-one basis and vest in 16 equal quarterly installments beginning one quarter after the grant date.
• The PSUs also convert into common stock on a one-for-one basis and vest in 16 equal quarterly installments beginning one quarter after the grant date, subject to the satisfaction of a milestone-based vesting condition.
• The PSU vesting condition is based on a net product sales revenue target for the fiscal year ending December 31, 2026, as reported in the Issuer's Form 10-K.
• Both grants were made at a price of $0 per unit, reflecting their nature as equity compensation.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the strong alignment of executive incentives with future company performance and shareholder value, despite the potential for future share dilution.

Positives

• The equity grants align the Chief Executive Officer's long-term incentives with shareholder value through both time-based (RSUs) and performance-based (PSUs) vesting conditions.
• The performance-based PSUs directly tie a significant portion of executive compensation to the achievement of net product sales revenue targets, indicating a focus on top-line growth.

Negatives

• The issuance of over 1.6 million new units represents potential future dilution for existing shareholders as these units convert into common stock upon vesting.

Risks

• The vesting of Performance Stock Units (PSUs) is contingent upon achieving a net product sales revenue target for the fiscal year ending December 31, 2026; failure to meet this target could result in a forfeiture of these units.
• Future stock price volatility could impact the ultimate value of these equity awards for the CEO and, by extension, the perceived effectiveness of the compensation structure.

Future Outlook

The vesting of a significant portion of the CEO's equity compensation is tied to achieving a net product sales revenue target for the fiscal year ending December 31, 2026, indicating a forward-looking focus on revenue growth.

Management Comments

• The grants reflect the company's compensation strategy to incentivize executive performance and align interests with long-term shareholder value.

Industry Context

StockSavvy.ai notes that equity grants, particularly those with performance-based vesting conditions, are a standard practice in the biotechnology and pharmaceutical industries. This approach is commonly used to attract and retain executive talent while motivating them to achieve specific operational and financial milestones, which is crucial for growth-oriented companies like Heron Therapeutics.

Comparison to Industry Standards

• The use of both time-based RSUs and performance-based PSUs is a common structure for executive equity compensation across the biotech and pharma sectors, mirroring practices seen in companies such as Amgen and Gilead Sciences.
• The specific size of the grant (over 1.6 million units) for a CEO of a company of Heron Therapeutics' market capitalization would typically be benchmarked against peer group compensation packages to ensure competitiveness and appropriate incentive alignment.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Craig A. Collard, the Chief Executive Officer and a Director, constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting of the units, but also benefit from aligned management incentives for revenue growth and long-term value creation.
• Employees: May signal management's confidence in future company performance, potentially boosting morale.
• Management (CEO): Receives significant equity compensation tied to both time and performance, incentivizing sustained leadership and strategic execution.

Next Steps

• The RSUs will begin vesting in quarterly installments one quarter after January 30, 2026.
• The PSUs will begin vesting in quarterly installments one quarter after January 30, 2026, contingent on the achievement of the net product sales revenue target for the fiscal year ending December 31, 2026.

Key Dates

Keywords

Heron Therapeutics, HRTX, Craig Collard, Restricted Stock Units, Performance Stock Units, Executive Compensation, Insider Transaction, Equity Grant, SEC Form 4